cefotaxime and Prostatic-Neoplasms

The simultaneous occurrence of carcinoma of the rectum and prostate is observed in 6%. Ablative surgery in two sessions is technically more difficult than in a single session. This is demonstrated by the successful outcome of a patient treated for such a double carcinoma without colostomy. In contrast to an accidental rectal injury, the thorough bowel preparation in this planned procedure enabled a single-session resection of the two cancers.

Topics: Anastomosis, Surgical; Antitrichomonal Agents; Cefotaxime; Cephalosporins; Humans; Male; Metronidazole; Middle Aged; Neoplasms, Multiple Primary; Prostatectomy; Prostatic Neoplasms; Rectal Neoplasms; Rectum; Surgical Wound Infection; Treatment Outcome

The incidence of preoperative and postoperative infections among 46 patients who underwent transurethral prostatectomy (TUR-P) was studied. Perioperative antibacterial schedule was as follows: one gram of cefotaxime (CTX) was intravenously injected just before the beginning of TUR-P, One gram of the antibiotic was intravenously infused once more on the day after TUR-P, twice on the next day, and once during each of the succeeding 2 days. Thirteen cases out of 46 (28.3%) had significant preoperative bacteriuria (greater than or equal to 1 X 10(4)/ml), but the postoperative eradication of the bacteria was observed for 10 of the 13 cases (76.9%). Among the 33 cases that did not have significant preoperative bacteriuria, only one case developed significant bacteriuria. In this case, a non-significant bacterial contamination of the urine had been observed before TUR-P.

Topics: Aged; Bacteriuria; Cefotaxime; Enterobacteriaceae Infections; Humans; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Neoplasms; Surgical Wound Infection

20, 30 and 90 minutes after a single intravenous injection of 2 g of cefotiam prostatic tissue and serum samples were taken from 12 patients who underwent transabdominal prostatectomy for prostatic adenoma. Cefotiam was assayed by HPLC. Mean serum and prostatic concentrations were respectively 157 +/- 39 mg/ml and 42 +/- 23 mg/g at 20 mn, 77 +/- 52 mg/ml and 54 +/- 2 mg/g at 30 mn, 36 +/- 21 mg/ml and 16 +/- 18 mg/g at 90 mn. Elimination half-life of cefotiam was 1 h 39 mn for serum and 1 h 10 mn for prostatic tissue. These findings confirm the satisfactory diffusion of cefotiam within prostatic tissue, although saturation occurs after 30 mn. Treatment of prostatitis by cefotiam can be expected to give excellent results.

Topics: Adenoma; Aged; Bacterial Infections; Cefotaxime; Cefotiam; Chromatography, High Pressure Liquid; Half-Life; Humans; Kinetics; Male; Prostate; Prostatectomy; Prostatic Neoplasms; Prostatitis

Topics: Bacteriuria; Cefotaxime; Epididymitis; Humans; Male; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Sepsis; Urinary Tract Infections

Within the framework of perioperative prophylaxis against infections, serum and tissue concentrations were measured following an i. v. bolus injection of 2.0 g of cefotaxime in 25 patients with a prostatic adenoma. The mean serum concentrations were 64.9 microgram/ml, 56.6 microgram/ml, 45.2 microgram/ml, 18.2 microgram/ml and 19.9 microgram/ml 30, 60, 90, 120 and 150 minutes respectively following the injection. The corresponding concentrations in the prostatic adenoma tissue were 8.8 microgram/g, 15.3 microgram/g, 22.9 microgram/g, 4.3 microgram/g and 2.7 microgram/g respectively. The tissue concentrations in ten testes from six patients were measured in a similar way. The maximum concentration (5.4 microgram/g) was also found to occur 90 minutes after the injection. We found very different values, ranging from 0.3 microgram/g to 39.6 microgram/g, in eight kidneys as a result of greatly differing diagnoses and function. Average concentrations of 9.2 microgram/g to 0.8 microgram/g in the ureter, fatty tissue and muscle tissue were within the therapeutically effective range. The cefotaxime concentrations found in serum and tissue lead us to expect successful therapy when cefotaxime is used to treat bacterial infections with sensitive pathogens in the urogenital tract.

Topics: Adenoma; Aged; Cefotaxime; Cephalosporins; Genitalia, Male; Humans; Kidney; Male; Prostate; Prostatic Neoplasms; Testis; Tissue Distribution; Ureter; Urinary Tract